214 related articles for article (PubMed ID: 12467703)
1. Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain.
Huang L; Brinen LS; Ellman JA
Bioorg Med Chem; 2003 Jan; 11(1):21-9. PubMed ID: 12467703
[TBL] [Abstract][Full Text] [Related]
2. Identification of a new class of nonpeptidic inhibitors of cruzain.
Brak K; Doyle PS; McKerrow JH; Ellman JA
J Am Chem Soc; 2008 May; 130(20):6404-10. PubMed ID: 18435536
[TBL] [Abstract][Full Text] [Related]
3. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
4. Cruzain structures: apocruzain and cruzain bound to S-methyl thiomethanesulfonate and implications for drug design.
Barbosa da Silva E; Dall E; Briza P; Brandstetter H; Ferreira RS
Acta Crystallogr F Struct Biol Commun; 2019 Jun; 75(Pt 6):419-427. PubMed ID: 31204688
[TBL] [Abstract][Full Text] [Related]
5. First quantum mechanics/molecular mechanics studies of the inhibition mechanism of cruzain by peptidyl halomethyl ketones.
Arafet K; Ferrer S; Moliner V
Biochemistry; 2015 Jun; 54(21):3381-91. PubMed ID: 25965914
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of chagasin, the endogenous cysteine-protease inhibitor from Trypanosoma cruzi.
Figueiredo da Silva AA; de Carvalho Vieira L; Krieger MA; Goldenberg S; Zanchin NI; Guimarães BG
J Struct Biol; 2007 Feb; 157(2):416-23. PubMed ID: 17011790
[TBL] [Abstract][Full Text] [Related]
7. Uncovering false positives on a virtual screening search for cruzain inhibitors.
Malvezzi A; de Rezende L; Izidoro MA; Cezari MH; Juliano L; do Amaral A
Bioorg Med Chem Lett; 2008 Jan; 18(1):350-4. PubMed ID: 17981033
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors.
Scheidt KA; Roush WR; McKerrow JH; Selzer PM; Hansell E; Rosenthal PJ
Bioorg Med Chem; 1998 Dec; 6(12):2477-94. PubMed ID: 9925304
[TBL] [Abstract][Full Text] [Related]
9. Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis.
Huang L; Lee A; Ellman JA
J Med Chem; 2002 Jan; 45(3):676-84. PubMed ID: 11806719
[TBL] [Abstract][Full Text] [Related]
10. Structural determinants of specificity in the cysteine protease cruzain.
Gillmor SA; Craik CS; Fletterick RJ
Protein Sci; 1997 Aug; 6(8):1603-11. PubMed ID: 9260273
[TBL] [Abstract][Full Text] [Related]
11. The crystal structure of cruzain: a therapeutic target for Chagas' disease.
McGrath ME; Eakin AE; Engel JC; McKerrow JH; Craik CS; Fletterick RJ
J Mol Biol; 1995 Mar; 247(2):251-9. PubMed ID: 7707373
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics simulations of the free and inhibitor-bound cruzain systems in aqueous solvent: insights on the inhibition mechanism in acidic pH.
Hoelz LV; Leal VF; Rodrigues CR; Pascutti PG; Albuquerque MG; Muri EM; Dias LR
J Biomol Struct Dyn; 2016 Sep; 34(9):1969-78. PubMed ID: 26414241
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
Chen YT; Brinen LS; Kerr ID; Hansell E; Doyle PS; McKerrow JH; Roush WR
PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20856868
[TBL] [Abstract][Full Text] [Related]
14. 2D QSAR and similarity studies on cruzain inhibitors aimed at improving selectivity over cathepsin L.
Freitas RF; Oprea TI; Montanari CA
Bioorg Med Chem; 2008 Jan; 16(2):838-53. PubMed ID: 17996450
[TBL] [Abstract][Full Text] [Related]
15. Leveraging the cruzain S3 subsite to increase affinity for reversible covalent inhibitors.
Cianni L; Sartori G; Rosini F; De Vita D; Pires G; Lopes BR; Leitão A; Burtoloso ACB; Montanari CA
Bioorg Chem; 2018 Sep; 79():285-292. PubMed ID: 29783099
[TBL] [Abstract][Full Text] [Related]
16. Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.
Mott BT; Ferreira RS; Simeonov A; Jadhav A; Ang KK; Leister W; Shen M; Silveira JT; Doyle PS; Arkin MR; McKerrow JH; Inglese J; Austin CP; Thomas CJ; Shoichet BK; Maloney DJ
J Med Chem; 2010 Jan; 53(1):52-60. PubMed ID: 19908842
[TBL] [Abstract][Full Text] [Related]
17. Divergent modes of enzyme inhibition in a homologous structure-activity series.
Ferreira RS; Bryant C; Ang KK; McKerrow JH; Shoichet BK; Renslo AR
J Med Chem; 2009 Aug; 52(16):5005-8. PubMed ID: 19637873
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Inhibitors of Cruzain Cysteine Protease of
Prates JLB; Lopes JR; Chin CM; Ferreira EI; Dos Santos JL; Scarim CB
Curr Med Chem; 2024; 31(16):2285-2308. PubMed ID: 37888814
[TBL] [Abstract][Full Text] [Related]
19. Experimental study and computational modelling of cruzain cysteine protease inhibition by dipeptidyl nitriles.
Dos Santos AM; Cianni L; De Vita D; Rosini F; Leitão A; Laughton CA; Lameira J; Montanari CA
Phys Chem Chem Phys; 2018 Sep; 20(37):24317-24328. PubMed ID: 30211406
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.
de Souza ML; de Oliveira Rezende Junior C; Ferreira RS; Espinoza Chávez RM; Ferreira LLG; Slafer BW; Magalhães LG; Krogh R; Oliva G; Cruz FC; Dias LC; Andricopulo AD
J Chem Inf Model; 2020 Feb; 60(2):1028-1041. PubMed ID: 31765144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
